Informations générales (source: ClinicalTrials.gov)
An International Field Study for the Reliability and Validity of the EORTC PATSAT-C33 and the EORTC OUT-PATSAT7 Questionnaires (PATSAT)
Observational
Institut Curie (Voir sur ClinicalTrials)
juillet 2020
juillet 2025
29 juin 2024
The aim of this study is to validate the EORTC PATSAT-C33 and EORTC OUT-PATSAT7
questionnaires scale structure in a large international field study.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | Anne BREDARD, pHd | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Institut de Cancérologie de Lorraine - 54519 - Vandœuvre-lès-Nancy - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
Patients regardless of cancer site or stage of disease (i.e. local, loco-regional,
metastatic, in remission) will be invited to participate if they meet the following
criteria:
1. Diagnosis of cancer confirmed histologically.
2. Patients are 18 years or older (to be adapted for compliance with each country
regulation).
3. Patients are willing to express their non-opposition to participate in the study.
4. Patients are able to read and understand the language of questionnaires.
5. Patients have the cognitive ability to complete the questionnaires.
6. Patients have had a sufficient experience of the cancer treatment setting :
a. For outpatients consulting in a chemotherapy day clinic/consultation for oral
treatment, ambulatory radiotherapy or consultation for follow-up surveillance to
check for signs of recurrence : i) between 3 to 6 cycles of chemotherapy or at least
2 cycles of other cancer treatment (e.g., biological oral therapy) or ii) between 2
to 6 weeks of radiotherapy or iii) within the 3rd to 24th month post-cancer
treatment. b. For inpatients consulting on an oncology or a surgery ward at least 3
days of hospital stay
Patients regardless of cancer site or stage of disease (i.e. local, loco-regional,
metastatic, in remission) will be invited to participate if they meet the following
criteria:
1. Diagnosis of cancer confirmed histologically.
2. Patients are 18 years or older (to be adapted for compliance with each country
regulation).
3. Patients are willing to express their non-opposition to participate in the study.
4. Patients are able to read and understand the language of questionnaires.
5. Patients have the cognitive ability to complete the questionnaires.
6. Patients have had a sufficient experience of the cancer treatment setting :
a. For outpatients consulting in a chemotherapy day clinic/consultation for oral
treatment, ambulatory radiotherapy or consultation for follow-up surveillance to
check for signs of recurrence : i) between 3 to 6 cycles of chemotherapy or at least
2 cycles of other cancer treatment (e.g., biological oral therapy) or ii) between 2
to 6 weeks of radiotherapy or iii) within the 3rd to 24th month post-cancer
treatment. b. For inpatients consulting on an oncology or a surgery ward at least 3
days of hospital stay
Patients will be excluded if they are :
1. Participating in another patient-reported outcome investigation that may interfere
with this study.
2. Experiencing any psychiatric condition or major cognitive impairment that may hamper
completion of self-reported questionnaires.